[HTML][HTML] Efficacy and response biomarkers of apatinib in the treatment of malignancies in China: a review
Z Tian, X Niu, W Yao - Frontiers in Oncology, 2021 - frontiersin.org
Apatinib is a multitarget tyrosine kinase inhibitor marketed in China for the treatment of
advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used …
advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used …
Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
Z Tian, X Niu, W Yao - Frontiers in oncology, 2021 - pubmed.ncbi.nlm.nih.gov
Apatinib is a multitarget tyrosine kinase inhibitor marketed in China for the treatment of
advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used …
advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used …
[HTML][HTML] Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
Z Tian, X Niu, W Yao - Frontiers in Oncology, 2021 - ncbi.nlm.nih.gov
Apatinib is a multitarget tyrosine kinase inhibitor marketed in China for the treatment of
advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used …
advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used …
Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review.
Z Tian, X Niu, W Yao - Frontiers in Oncology, 2021 - europepmc.org
Apatinib is a multitarget tyrosine kinase inhibitor marketed in China for the treatment of
advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used …
advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used …